Richard J Jones

List of Publications by Year
in descending order

264 papers	17,533 citations	18887 64 h-index	18400 124 g-index
266 all docs	266 docs citations	266 times ranked	15249 citing authors

#	Article	IF	Citations
1	Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia, 2022, 36, 856-864.	3.3	26
2	Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood, 2022, 139, 608-623.	0.6	42
3	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. Journal of Clinical Oncology, 2022, 40, 189-201.	0.8	79
4	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. Transplantation and Cellular Therapy, 2022, 28, 109.e1-109.e8.	0.6	12
5	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitorâ€“Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology, 2022, 40, 356-368.	0.8	79
6	Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. Transplantation and Cellular Therapy, 2022, 28, 259.e1-259.e11.	0.6	11
7	Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Advances, 2022, 6, 2520-2534.	2.5	19
8	CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia. Leukemia and Lymphoma, 2022, 63, 1617-1623.	0.6	3
9	Incidence and Outcomes of Respiratory Failure after Nonmyeloablative Related Haploidentical Blood or Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28, 160.e1-160.e8.	0.6	2
10	Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leukemia and Lymphoma, 2022, 63, 1942-1948.	0.6	8
11	The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. Science Advances, 2022, 8, eabl8952.	4.7	7
12	Abstract 5435: CCRL2 affects the sensitivity of MDS and secondary AML to azacitidine. Cancer Research, 2022, 82, 5435-5435.	0.4	0
13	The next horizon now that everyone has a donor: Precision allogeneic transplantation. Blood Reviews, 2022, , 100990.	2.8	2
14	Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. Transplantation and Cellular Therapy, 2021, 27, 183.e1-183.e7.	0.6	6
15	Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes. Journal of Clinical Immunology, 2021, 41, 414-426.	2.0	12
16	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood, 2021, 137, 420-428.	0.6	119
17	Pain Experiences of Adults With Sickle Cell Disease and Hematopoietic Stem Cell Transplantation: A Qualitative Study. Pain Medicine, 2021, 22, 1753-1759.	0.9	4
18	Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Advances, 2021, 5, 1360-1368.	2.5	39

#	Article	IF	Citations
19	Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. International Journal of Molecular Sciences, 2021, 22, 2595.	1.8	10
20	Genderâ€related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. British Journal of Haematology, 2021, 193, 1142-1150.	1.2	21
21	Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood, 2021, 138, 942-947.	0.6	49
22	A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia and Lymphoma, 2021, 62, 3181-3191.	0.6	4
23	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplantation and Cellular Therapy, 2021, 27, 885-907.	0.6	12
24	Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2021, 27, 909.e1-909.e6.	0.6	7
25	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 863.e1-863.e5.	0.6	4
26	A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leukemia Research, 2021, 111, 106737.	0.4	4
27	Acquired Aplastic Anemia. , 2020, , 923-934.		0
28	A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 300-306.	2.0	36
29	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 502-508.	2.0	9
30	Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 2075-2081.	2.0	17
31	The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. Journal of Molecular Medicine, 2020, 98, 1161-1173.	1.7	6
32	Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. Leukemia Research, 2020, 99, 106477.	0.4	8
33	A Phase 1 Study of IRX195183, a RARÎ±-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML. Frontiers in Oncology, 2020, 10, 587062.	1.3	3
34	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV,the, 2020, 7, e602-e610.	2.1	11
35	Activating KRAS , NRAS , and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20004-20014.	3.3	42
36	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Advances, 2020, 4, 5078-5088.	2.5	23

#	Article	IF	Citations
37	Assessing Early Supportive Care Needs among Son or Daughter Haploidentical Transplantation Donors. Biology of Blood and Marrow Transplantation, 2020, 26, 2121-2126.	2.0	0
38	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Advances, 2020, 4, 3913-3925.	2.5	52
39	Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors. Frontiers in Immunology, 2020, 11, 1816.	2.2	5
40	Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2020, 26, 2306-2310.	2.0	8
41	Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Advances, 2020, 4, 1770-1779.	2.5	92
42	Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids. Leukemia, 2020, 34, 3077-3081.	3.3	14
43	Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. Biology of Blood and Marrow Transplantation, 2020, 26, 1679-1688.	2.0	25
44	Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2431-2437.	2.0	54
45	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN 0903/AMC-080 Trial. Biology of Blood and Marrow Transplantation, 2019, 25, 2160-2166.	2.0	27
46	Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation: The struggle to unlearn. Best Practice and Research in Clinical Haematology, 2019, 32, 101112.	0.7	0
47	R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. Leukemia and Lymphoma, 2019, 60, 1261-1265.	0.6	14
48	Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance. Advances in Experimental Medicine and Biology, 2019, 1139, 153-169.	0.8	23
49	Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?. Current Oncology Reports, 2019, 21, 65.	1.8	2
50	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?. Journal of Clinical Oncology, 2019, 37, 1604-1607.	0.8	29
51	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematology,the, 2019, 6, e183-e193.	2.2	111
52	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematology,the, 2019, 6, e132-e143.	2.2	200
53	Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment. Journal of Cellular and Molecular Medicine, 2019, 23, 4111-4117.	1.6	11
54	Role of CYP3A4 in bone marrow microenvironmentâ€“mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. Blood Advances, 2019, 3, 908-916.	2.5	49

#	Article	IF	Citations
55	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Advances, 2019, 3, 2608-2616.	2.5	20
56	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2019, 25, 1128-1135.	2.0	38
57	Hematopoiesis. , 2019, , 5-13.		0
58	Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD). Blood, 2019, 134, 3320-3320.	0.6	1
59	A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance. Blood, 2019, 134, 778-778.	0.6	3
60	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1022-1028.	2.0	29
61	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Nonâ€“First-Degree Related Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1099-1102.	2.0	61
62	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biology of Blood and Marrow Transplantation, 2018, 24, 1274-1280.	2.0	46
63	Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia, 2018, 32, 2224-2239.	3.3	66
64	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, 343-352.	2.0	61
65	Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia. Leukemia and Lymphoma, 2018, 59, 1231-1238.	0.6	8
66	Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Advances, 2018, 2, 2226-2229.	2.5	47
67	Should an HLA-matched donor still be considered the perfect donor?. Lancet Haematology,the, 2018, 5, e388-e390.	2.2	4
68	Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment. Biology of Blood and Marrow Transplantation, 2018, 24, e26-e30.	2.0	16
69	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 2056-2064.	2.0	32
70	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2017, 23, 612-617.	2.0	17
71	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica, 2017, 102, 391-400.	1.7	152
72	Haplotype Counting for Sensitive Chimerism Testing. Journal of Molecular Diagnostics, 2017, 19, 427-436.	1.2	10

#	Article	IF	Citations
73	RNA Polymerase I Inhibition with CXâ€5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. British Journal of Haematology, 2017, 177, 80-94.	1.2	51
74	Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2017, 23, 498-504.	2.0	93
75	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood, 2017, 129, 1389-1393.	0.6	69
76	Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinaseâ€"Driven Leukemias and Other Malignancies. Cancer Research, 2017, 77, 5554-5563.	0.4	36
77	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 1903-1909.	2.0	14
78	Retinoic acid, CYP26, and drug resistance in the stem cell niche. Experimental Hematology, 2017, 54, 17-25.	0.2	21
79	Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1887-1894.	2.0	42
80	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. Biology of Blood and Marrow Transplantation, 2017, 23, 2127-2136.	2.0	17
81	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 325-332.	2.0	61
82	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Advances, 2017, 1, 288-292.	2.5	84
83	Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies. Leukemia Research, 2016, 49, 90-97.	0.4	11
84	Translating leukemia stem cells into the clinical setting: Harmonizing theÂheterogeneity. Experimental Hematology, 2016, 44, 1130-1137.	0.2	17
85	All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. Blood, 2016, 127, 2867-2878.	0.6	40
86	High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. Journal of Pediatric Hematology/Oncology, 2016, 38, 627-635.	0.3	11
87	Association of acute myeloid leukemias most immature phenotype with risk groups and outcomes. Haematologica, 2016, 101, 607-616.	1.7	21
88	Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epsteinâ€"Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. Clinical Cancer Research, 2016, 22, 4901-4912.	3.2	41
89	Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy. Gynecologic Oncology, 2016, 142, 341-348.	0.6	41
90	Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leukemia and Lymphoma, 2016, 57, 666-675.	0.6	11

#	Article	IF	Citations
91	Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. Journal of Clinical Investigation, 2016, 126, 4460-4468.	3.9	35
92	Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction. Blood, 2016, 128, 831-831.	0.6	3
93	Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. International Journal of Cancer, 2015, 136, 991-1002.	2.3	15
94	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood, 2015, 125, 3024-3031.	0.6	259
95	Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Science Translational Medicine, 2015, 7, 288ra78.	5.8	104
96	Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Largest Reported Experience with High Risk Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, S29.	2.0	9
97	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2015, 21, 2538-2545.	3.2	19
98	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biology of Blood and Marrow Transplantation, 2015, 21, 2115-2122.	2.0	26
99	The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?. Leukemia and Lymphoma, 2015, 56, 128-134.	0.6	20
100	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. Journal of Clinical Oncology, 2015, 33, 3152-3161.	0.8	215
101	RAR-Alpha Targeting Compounds Overcome Bone Marrow (BM) Stromal Protection of AML By CYP26. Blood, 2015, 126, 2474-2474.	0.6	1
102	Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation. Blood, 2015, 126, 3164-3164.	0.6	24
103	FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment. Blood, 2015, 126, 790-790.	0.6	9
104	All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment. PLoS ONE, 2015, 10, e0127790.	1.1	54
105	Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes. Oncotarget, 2015, 6, 14905-14912.	0.8	44
106	Haplo-Identical Bone Marrow Transplant Protocol using Reduced Intensity Conditioning for Fundeni Clinical Institute. Acta Geographica Slovenica, 2015, 34, 32-38.	0.3	0
107	HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 314-318.	2.0	103
108	Acquired Aplastic Anemia. , 2014, , 685-694.		2

#	Article	IF	Citations
109	Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning. Journal of Clinical Oncology, 2014, 32, 3497-3505.	0.8	234
110	Isolated Clonal Cytogenetic Abnormalities after High-Dose Therapy. Biology of Blood and Marrow Transplantation, 2014, 20, 1130-1138.	2.0	9
111	Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-Î± (IFN) in newly diagnosed chronic myeloid leukemia (CML). Leukemia Research, 2014, 38, 886-890.	0.4	8
112	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood, 2014, 124, 3817-3827.	0.6	165
113	Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy). Blood, 2014, 124, 730-730.	0.6	5
114	Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737. PLoS ONE, 2014, 9, e103015.	1.1	26
115	Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide. Science Translational Medicine, 2013, 5, 211ra157.	5.8	303
116	Regulation of human hematopoietic stem cell self-renewal by the microenvironmentâ€™s control of retinoic acid signaling. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16121-16126.	3.3	116
117	Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2013, 19, 1514-1517.	2.0	103
118	Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies. Biology of Blood and Marrow Transplantation, 2013, 19, 647-652.	2.0	113
119	Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2013, 19, 602-606.	2.0	87
120	Targeted Pathologic Evaluation of Bone Marrow Donors Identifies Previously Undiagnosed Marrow Abnormalities. Biology of Blood and Marrow Transplantation, 2013, 19, 1254-1259.	2.0	7
121	In utero Hematopoietic Stem Cell Transplantation in Canines: Exploring the Gestational Age Window of Opportunity to Maximize Engraftment. Fetal Diagnosis and Therapy, 2013, 33, 116-121.	0.6	9
122	Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leukemia and Lymphoma, 2013, 54, 483-490.	0.6	13
123	The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 381-392.	1.3	20
124	Single Cell Analysis Of JAK2V617F Positive MPN Stem/Progenitor Cells In Chronic Phase and Leukemic Transformation. Blood, 2013, 122, 1609-1609.	0.6	1
125	Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy). Blood, 2013, 122, 3407-3407.	0.6	2
126	The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy). Blood, 2013, 122, 4629-4629.	0.6	1

#	Article	IF	Citations
127	Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget, 2013, 4, 715-728.	0.8	92
128	All-Trans Retinoic Acid Synergizes With FLT3 Tyrosine Kinase Inhibition To Eliminate FLT3/ITD-Expressing Leukemia Cells. Blood, 2013, 122, 3960-3960.	0.6	1
129	Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases. American Journal of Blood Research, 2013, 3, 84-90.	0.6	13
130	Treatment of relapsingâ€“remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Multiple Sclerosis Journal, 2012, 18, 202-209.	1.4	24
131	Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA. Molecular Cancer Therapeutics, 2012, 11, 2243-2253.	1.9	47
132	Cancer stem cells. Current Opinion in Oncology, 2012, 24, 170-175.	1.1	9
133	A clinically relevant population of leukemic CD34+CD38â^' cells in acute myeloid leukemia. Blood, 2012, 119, 3571-3577.	0.6	191
134	Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood, 2012, 120, 3260-3270.	0.6	165
135	Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood, 2012, 119, 4129-4132.	0.6	67
136	HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood, 2012, 120, 4285-4291.	0.6	387
137	Pluripotent Stem Cellâ€“Based Cancer Therapy: Promise and Challenges. Science Translational Medicine, 2012, 4, 127ps9.	5.8	49
138	Haploidentical Transplantation: RepurposingÂCyclophosphamide. Biology of Blood and Marrow Transplantation, 2012, 18, 1771-1772.	2.0	18
139	The Importance of IGHV Mutational Status in del(11q) and del(17p) Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 132-137.	0.2	19
140	Concise Review: Cancer Stem Cells and Minimal Residual Disease. Stem Cells, 2012, 30, 89-93.	1.4	71
141	Hematopoietic Stem Cell (HSC) Self-Renewal Is Determined by the Bone Marrow (BM) Microenvironment's Regulation of Retinoic Acid (RA) Signaling.. Blood, 2012, 120, 2346-2346.	0.6	0
142	High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leukemia and Lymphoma, 2011, 52, 2076-2081.	0.6	8
143	Extended Follow-up of Autologous Bone Marrow Transplantation with 4-Hydroperoxycyclophosphamide (4-HC) Purging for Indolent or Transformed Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation, 2011, 17, 365-373.	2.0	6
144	5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 754-758.	2.0	58

#	Article	IF	Citations
145	Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution. Biology of Blood and Marrow Transplantation, 2011, 17, 1404-1409.	2.0	128
146	High-Dose Cyclophosphamide Without Stem Cell Rescue in 207 Patients With Aplastic Anemia and Other Autoimmune Diseases. Medicine (United States), 2011, 90, 89-98.	0.4	37
147	HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood, 2011, 118, 4140-4149.	0.6	36
148	High-Dose Cyclophosphamide Without Stem Cell Rescue for the Treatment of Refractory Behcet's Disease. Seminars in Arthritis and Rheumatism, 2011, 41, 301-304.	1.6	4
149	Characterization of chronic myeloid leukemia stem cells. American Journal of Hematology, 2011, 86, 31-37.	2.0	78
150	Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leukemia Research, 2011, 35, 87-94.	0.4	19
151	Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 1873-1881.	0.6	17
152	Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation with High Dose, Post-Transplantation Cyclophosphamide. Mental Illness, 2011, 3, e15.	0.8	66
153	Ex Vivo Graft Purging and Expansion of Autologous Blood Progenitor Cell Products from Patients with Multiple Myeloma. Cancer Research, 2011, 71, 5040-5049.	0.4	14
154	Desensitization for Mismatched Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2011, 118, 1955-1955.	0.6	7
155	The Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Blood, 2011, 118, 240-240.	0.6	3
156	Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial,. Blood, 2011, 118, 4151-4151.	0.6	11
157	High-dose cyclophosphamide for graft-versus-host disease prevention. Current Opinion in Hematology, 2010, 17, 493-499.	1.2	84
158	High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood, 2010, 115, 2136-2141.	0.6	107
159	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood, 2010, 115, 3224-3230.	0.6	346
160	Highâ€dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: A prospective randomized trial. Arthritis and Rheumatism, 2010, 62, 1487-1493.	6.7	43
161	Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leukemia Research, 2010, 34, 877-882.	0.4	78
162	Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats. Journal of Ovarian Research, 2010, 3, 9.	1.3	6

#	Article	IF	Citations
163	Epstein-Barr virus-specific methylation of human genes in gastric cancer cells. Infectious Agents and Cancer, 2010, 5, 27.	1.2	54
164	Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biology of Blood and Marrow Transplantation, 2010, 16, 482-489.	2.0	260
165	Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 533-542.	2.0	168
166	Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms. PLoS ONE, 2010, 5, e12487.	1.1	63
167	Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes. Clinical Cancer Research, 2009, 15, 7217-7228.	3.2	196
168	Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Experimental Hematology, 2009, 37, 42-51.e1.	0.2	34
169	Silencing of genes required for glycosylphosphatidylinositol anchor biosynthesis in Burkitt lymphoma. Experimental Hematology, 2009, 37, 423-434.e2.	0.2	19
170	Cancer stem cellsâ€"clinical relevance. Journal of Molecular Medicine, 2009, 87, 1105-1110.	1.7	21
171	Controversies in cancer stem cells. Journal of Molecular Medicine, 2009, 87, 1077-1078.	1.7	4
172	Cyclophosphamide and cancer: golden anniversary. Nature Reviews Clinical Oncology, 2009, 6, 638-647.	12.5	675
173	Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood, 2009, 113, 5920-5926.	0.6	159
174	Response: Hodgkin lymphoma stem cells. Blood, 2009, 114, 3971-3972.	0.6	3
175	Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leukemia Research, 2008, 32, 1439-1447.	0.4	18
176	Rebooting the Immune System with Highâ€Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis. Annals of the New York Academy of Sciences, 2008, 1132, 305-314.	1.8	88
177	Cancer Stem Cells in Hematopoietic Malignancies. Biology of Blood and Marrow Transplantation, 2008, 14, 12-16.	2.0	19
178	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2008, 14, 641-650.	2.0	1,525
179	Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2008, 14, 1279-1287.	2.0	251
180	Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: Advantages and disadvantages. Autoimmunity, 2008, 41, 596-600.	1.2	15

#	Article	IF	Citations
181	Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. Cancer Research, 2008, 68, 190-197.	0.4	495
182	Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damageâ€“Independent p53 Phosphorylation in Mantle Cell Lymphoma. Clinical Cancer Research, 2008, 14, 5416-5425.	3.2	30
183	Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis. Archives of Neurology, 2008, 65, 1044-51.	4.9	78
184	The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood, 2008, 112, 504-510.	0.6	128
185	Post-Transplantation High Dose Cyclophosphamide (Cy) Is Effective Single Agent for Prevention of Acute and Chronic Graft Versus Host Disease after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT). Blood, 2008, 112, 56-56.	0.6	6
186	Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia. Clinical Cancer Research, 2007, 13, 4467-4473.	3.2	87
187	Epstein-Barr Virus Lytic Infection Induces Retinoic Acid-responsive Genes through Induction of a Retinol-metabolizing Enzyme, DHRS9. Journal of Biological Chemistry, 2007, 282, 8317-8324.	1.6	34
188	ZEB1 and c-Jun Levels Contribute to the Establishment of Highly Lytic Epstein-Barr Virus Infection in Gastric AGS Cells. Journal of Virology, 2007, 81, 10113-10122.	1.5	49
189	Use of T-Cell Antibodies for Donor Dosaging in a Canine Model of in utero Hematopoietic Stem Cell Transplantation. Fetal Diagnosis and Therapy, 2007, 22, 175-179.	0.6	18
190	Cancer Stem Cells: From Bench to Bedside. Biology of Blood and Marrow Transplantation, 2007, 13, 47-52.	2.0	18
191	Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma. Biology of Blood and Marrow Transplantation, 2007, 13, 1185-1191.	2.0	24
192	Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. International Journal of Cancer, 2007, 121, 1274-1281.	2.3	55
193	Treatment of hepatitisâ€associated aplastic anemia with highâ€dose cyclophosphamide. Pediatric Blood and Cancer, 2007, 49, 947-951.	0.8	21
194	Venous Thromboembolism among 1,570 Patients Undergoing Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment and Outcomes.. Blood, 2007, 110, 1628-1628.	0.6	1
195	Risk-Adapted Therapy of Aggressive Lymphoma Based on FDG-PET Performed after 2 or 3 Cycles of Initial Chemotherapy.. Blood, 2007, 110, 1894-1894.	0.6	2
196	Stem Cell Transplantation for AML. , 2007, , 313-327.		0
197	Graft-versus-Host Reactions and the Effectiveness of Donor Lymphocyte Infusions. Biology of Blood and Marrow Transplantation, 2006, 12, 414-421.	2.0	56
198	Long-Term Follow-up of Allogeneic Marrow Transplantation for Acute Myelogenous Leukemia after Treatment with Busulfan and Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2006, 12, 366-367.	2.0	5

#	Article	IF	Citations
199	Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkinâ€™s Lymphoma. Biology of Blood and Marrow Transplantation, 2006, 12, 965-972.	2.0	44
200	Strategies to eliminate cancer stem cells: Clinical implications. European Journal of Cancer, 2006, 42, 1293-1297.	1.3	52
201	The paradox of response and survival in cancer therapeutics. Blood, 2006, 107, 431-434.	0.6	146
202	Cancer Stem Cell Targeting in Multiple Myeloma by GRN163L, a Novel and Potent Telomerase Inhibitor.. Blood, 2006, 108, 2540-2540.	0.6	13
203	Clonotypic B Cells Circulate in Hodgkinâ€™s Lymphoma (HL).. Blood, 2006, 108, 470-470.	0.6	6
204	Myeloablative Allogeneic Bone Marrow Transplantation (AlloBMT) with T Cell Depletion (TCD) and Post-Transplant GM-CSF for Patients with High Risk MDS.. Blood, 2006, 108, 5309-5309.	0.6	0
205	PIG-A mutations in normal hematopoiesis. Blood, 2005, 105, 3848-3854.	0.6	116
206	Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia. British Journal of Haematology, 2005, 128, 853-862.	1.2	34
207	Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. British Journal of Haematology, 2005, 130, 373-381.	1.2	87
208	Aplastic anaemia. Lancet, The, 2005, 365, 1647-1656.	6.3	251
209	Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biology of Blood and Marrow Transplantation, 2005, 11, 39-46.	2.0	43
210	High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biology of Blood and Marrow Transplantation, 2005, 11, 93-100.	2.0	43
211	High Dose Cyclophosphamide (CY) for Severe Aplastic Anemia (SAA): Safety and Long Term Follow-Up.. Blood, 2005, 106, 129-129.	0.6	3
212	Differentiation Therapy for Poor Risk Myeloid Malignancies: Results of a Dose Finding Study of Bryostatin-1 (BRYO) + GM-CSF.. Blood, 2005, 106, 2792-2792.	0.6	2
213	K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).. Blood, 2005, 106, 2858-2858.	0.6	0
214	Cancer Stem Cells: Are We Missing the Target?. Journal of the National Cancer Institute, 2004, 96, 583-585.	3.0	166
215	High-dose cyclophosphamide in severe aplastic anaemia. British Journal of Haematology, 2004, 125, 408-409.	1.2	3
216	High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Experimental Hematology, 2004, 32, 435-440.	0.2	43

#	Article	IF	Citations
217	Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant. Current Opinion in Oncology, 2004, 16, 95-99.	1.1	31
218	Characterization of clonogenic multiple myeloma cells. Blood, 2004, 103, 2332-2336.	0.6	738
219	Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood, 2004, 104, 2187-2193.	0.6	284
220	Multiple Myeloma Stem Cells and Plasma Cells Display Distinct Drug Sensitivities.. Blood, 2004, 104, 2476-2476.	0.6	4
221	Post-Transplantation Cyclophosphamide (Cy) Reduces Graft Rejection and Graft-Versus-Host Disease (GVHD) after Non-Myeloablative, Partially HLA-Mismatched (Haploidentical) Bone Marrow Transplantation (BMT).. Blood, 2004, 104, 437-437.	0.6	6
222	Treatment of refractory myasthenia: ?Rebooting? with high-dose cyclophosphamide. Annals of Neurology, 2003, 53, 29-34.	2.8	127
223	High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 48, 166-173.	6.7	136
224	Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation. British Journal of Haematology, 2003, 121, 251-258.	1.2	38
225	Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biology of Blood and Marrow Transplantation, 2003, 9, 312-319.	2.0	31
226	Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and Î²-thalassemia. Biology of Blood and Marrow Transplantation, 2003, 9, 519-528.	2.0	253
227	High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood, 2002, 100, 704-706.	0.6	103
228	Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience. British Journal of Haematology, 2002, 117, 907-913.	1.2	17
229	The role of growth factors in the activity of pharmacological differentiation agents. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 2002, 13, 275-83.	0.8	12
230	Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biology of Blood and Marrow Transplantation, 2001, 7, 561-567.	2.0	22
231	High-dose cyclophosphamide in aplastic anaemia. Lancet, The, 2001, 357, 1128-1129.	6.3	10
232	Long-Term Results of Blood and Marrow Transplantation for Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2001, 19, 4314-4321.	0.8	163
233	ELIMINATION OF ALLOANTIBODIES BY IMMUNOABLATIVE HIGH-DOSE CYCLOPHOSPHAMIDE 1. Transplantation, 2001, 71, 482-484.	0.5	18
234	Leukemic stem cells: where have they gone wrong?. Blood, 2001, 97, 3681-3682.	0.6	9

#	Article	IF	Citations
235	Durable Treatment-Free Remission after High-Dose Cyclophosphamide Therapy for Previously Untreated Severe Aplastic Anemia. Annals of Internal Medicine, 2001, 135, 477.	2.0	95
236	Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. British Journal of Haematology, 2001, 115, 476-482.	1.2	88
237	Transmission of a T-Cell Lymphoma by Allogeneic Bone Marrow Transplantation. New England Journal of Medicine, 2001, 345, 1458-1463.	13.9	80
238	New Developments in the Therapy of Acute Myelocytic Leukemia. Hematology American Society of Hematology Education Program, 2000, 2000, 69-89.	0.9	17
239	A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer. Cancer Investigation, 2000, 18, 521-529.	0.6	166
240	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America, 2000, 26, 377-387.	0.8	17
241	New Developments in the Therapy of Acute Myelocytic Leukemia. Hematology American Society of Hematology Education Program, 2000, 2000, 69-89.	0.9	2
242	New Developments in the Therapy of Acute Myelocytic Leukemia. Hematology American Society of Hematology Education Program, 2000, 2000, 69-89.	0.9	2
243	Resistance of Paroxysmal Nocturnal Hemoglobinuria Cells to the Glycosylphosphatidylinositol-Binding Toxin Aerolysin. Blood, 1999, 93, 1749-1756.	0.6	92
244	Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia. Biology of Blood and Marrow Transplantation, 1999, 5, 394-399.	2.0	15
245	Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease. Journal of the American Academy of Dermatology, 1999, 40, 750-754.	0.6	62
246	Inhibited apoptosis and drug resistance in acute myeloid leukaemia. British Journal of Haematology, 1998, 102, 1042-1049.	1.2	41
247	Specificity of Effector T Lymphocytes in Autologous Graft-Versus-Host Disease: Role of the Major Histocompatibility Complex Class II Invariant Chain Peptide. Blood, 1997, 89, 2203-2209.	0.6	75
248	Phenotypic and functional characterization of the hematopoietic stem cell. Stem Cells, 1997, 15, 41-45.	1.4	28
249	Antitumor Activity of Syngeneic/Autologous Graft-versus-Host Disease. Annals of the New York Academy of Sciences, 1995, 770, 189-202.	1.8	6
250	Pharmacology of Bone Marrow Transplantation Conditioning Regimens. Annals of the New York Academy of Sciences, 1995, 770, 237-241.	1.8	6
251	Analysis of the V? T-Cell Receptor Repertoire in Autologous Graft-versus-Host Disease. Annals of the New York Academy of Sciences, 1995, 756, 432-434.	1.8	2
252	Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation. Breast Cancer Research and Treatment, 1993, 26, S31-S40.	1.1	9

#	Article	IF	Citations
253	Cyclosporine-Induced Graft-versus-Host Disease after Autologous Bone Marrow Transplantation for Acute Myeloid Leukemia. Leukemia and Lymphoma, 1993, 11, 215-220.	0.6	20
254	Purging With 4-Hydroperoxycyclophosphamide. Stem Cells and Development, 1992, 1, 343-348.	1.0	16
255	Autologous graft-versus-host disease: A novel approach for antitumor immunotherapy. Human Immunology, 1992, 34, 219-224.	1.2	26
256	Fluorescence in situ hybridization to determine engraftment status after murine bone marrow transplant. Cancer Genetics and Cytogenetics, 1992, 64, 145-148.	1.0	27
257	Oral mucositis after bone marrow transplantation. Oral Surgery, Oral Medicine, and Oral Pathology, 1991, 72, 419-424.	0.6	32
258	Separation of pluripotent haematopoietic stem cells from spleen colony-forming cells. Nature, 1990, 347, 188-189.	13.7	382
259	Autologous Bone Marrow Transplantation. Annual Review of Medicine, 1989, 40, 99-112.	5.0	43
260	Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemotherapy and Pharmacology, 1989, 25, 55-61.	1.1	387
261	VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION. Transplantation, 1987, 44, 778-783.	0.5	807
262	Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, andm-AMSA. Arthritis and Rheumatism, 1987, 30, 1187-1190.	6.7	29
263	Amino Acid Sequence of the Hemoglobin of Raccoon (Procyon lotor). Hemoglobin, 1978, 2, 351-370.	0.4	10
264	Autologous Graft-vs.-Host Disease. , 0, , 405-413.		0